| Literature DB >> 26558124 |
Geoffrey Alan Watson1, Lorraine O'Neill1, Ruth Law1, Geraldine McCarthy2, Douglas Veale1.
Abstract
Malignant disease may be associated with a wide variety of musculoskeletal syndromes. Rarely the musculoskeletal system can be indirectly affected by paraneoplastic phenomena, such as carcinomatous polyarthritis (CP). The differential diagnosis for CP is broad and is often a diagnosis of exclusion. CP often presents similarly to other forms of inflammatory arthritis, and a detailed history and physical examination can often distinguish CP from other more common causes of polyarticular arthritis. However serological tests such as rheumatoid factor (RF) and anti-citrullinated peptide (anti-CCP) antibody positivity, while rare, can be misleading. Clinical awareness and suspicion are paramount in achieving an accurate diagnosis and early detection of an occult neoplasm is critical for prompt management and therapy. We report two cases presenting with this unique clinical phenotype associated with paraneoplastic polyarthropathy and review the literature.Entities:
Year: 2015 PMID: 26558124 PMCID: PMC4629013 DOI: 10.1155/2015/934039
Source DB: PubMed Journal: Case Rep Oncol Med
Figure 1CT of abdomen. The red arrow illustrates a well circumscribed, multilobulated 3.3 cm lesion in the inferior outer quadrant of the right breast.
Figure 2Encapsulated papillary carcinoma showing classical papillary architecture with surrounding fibrous capsule.
Malignancies associated with carcinomatous polyarthritis. Four cases, highlighted in bold, have shown anti-CCP positivity. Rheumatoid factor (RF), anti-citrullinated protein antibody (anti-CCP), positive (+), negative (−), not included (NI), Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Cancer (SCC), Small Cell Lung Cancer (SCLC), Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Chronic Lymphoid Leukemia (CLL).
| Case report and reference | Type of malignancy | RF | Anti-CCP |
|---|---|---|---|
|
|
|
|
|
| Present case | NSCLC | − | − |
| Zupancic et al. [ | SCC lung | + | NI |
| Stummvoll et al. [ | Adenocarcinoma colon | − | NI |
|
Stummvoll et al. [ | SCC Lung | − | NI |
|
|
|
|
|
| Nadal et al. [ | Prostate cancer | NI | − |
| Bradley and Pinals [ | Spindle cell cancer | + | NI |
| Pines et al. [ | Breast | − | NI |
| Pines et al. [ | Unknown primary | − | NI |
| Pines et al. [ | SCLC | − | NI |
| Acosta Madiedo et al. [ | NSCLC | − | NI |
| Chuan et al. [ | Tubular adenocarcinoma stomach | − | NI |
| Eggelmeijer and Macfarlane [ | Supraglottic SCC | − | NI |
| Bennett et al. [ | Ovarian adenocarcinoma | + | NI |
| Simon and Ford [ | Adenocarcinoma colon | − | NI |
| Mok and Kwan [ | Unknown primary | + | NI |
|
|
|
|
|
|
|
|
|
|
| Sheehy et al. [ | NSCLC (adenocarcinoma) | + | NI |
| Bivalacqua et al. [ | NSCLC (adenocarcinoma) | NI | NI |
| Docquier et al. [ | Uterine adenocarcinoma | − | NI |
| Haroon and Phelan [ | Pancreatic cancer | − | NI |
| Ardalan and Shoja [ | Multiple myeloma | − | NI |
| Leslie [ | Cervical cancer | NI | NI |
| Baijens and Manni [ | cT4N2cM0 hypopharynx carcinoma | NI | NI |
| Martorell et al. [ | Serocystadenocarcinoma ovary | − | NI |
| Martorell et al. [ | Serocystadenocarcinoma ovary | + | NI |
| Martorell et al. [ | Ovarian carcinoma | − | NI |
| Martorell et al. [ | Serocystadenocarcinoma ovary | − | NI |
| Medsger et al. [ | Ovarian adenocarcinoma | NI | NI |
| Medsger et al. [ | Ovarian adenocarcinoma | NI | NI |
| Medsger et al. [ | Ovarian adenocarcinoma | NI | NI |
| Medsger et al. [ | Ovarian adenocarcinoma | NI | NI |
| Medsger et al. [ | Ovarian adenocarcinoma | NI | NI |
| Medsger et al. [ | Ovarian adenocarcinoma | NI | NI |
| Baron [ | SCLC | − | NI |
| Baer and Phillips [ | Pancreatic adenocarcinoma | NI | NI |
| Taggart et al. [ | Adenocarcinoma Fallopian tube | − | NI |
| Taggart et al. [ | Ovarian adenocarcinoma | NI | NI |
| Michaels and Sorber [ | Pancreatic adenocarcinoma | − | NI |
| Shiel et al. [ | SCLC | NI | NI |
| Shiel et al. [ | Ovarian adenocarcinoma | NI | NI |
| Pfinsgraff et al. [ | CML | − | NI |
| Pfinsgraff et al. [ | Pancreatic adenocarcinoma, parathyroid adenoma | NI | NI |
| Pfinsgraff et al. [ | Squamous cell carcinoma unknown primary | − | NI |
| Pfinsgraff et al. [ | Adenocarcinoma unknown primary | NI | NI |
| Pfinsgraff et al. [ | Hodgkin disease | NI | NI |
| Valverde-Garcia et al. [ | Breast cancer | NI | NI |
| Cammilleri et al. [ | Follicular B cell lymphoma | − | NI |
| Willemse et al. [ | Adenocarcinoma of the coelomic epithelium | − | NI |
| Van den Bergh et al. [ | Adenocarcinoma of prostate prolactinoma | − | NI |
| Mathieu et al. [ | CLL | NI | NI |
| Vinker et al. [ | Ovarian adenocarcinoma | NI | NI |
| Saxman and Seitz [ | Breast carcinoma | − | NI |
| Grados et al. [ | Transitional cell carcinoma of the renal pelvis | − | NI |
| Grados et al. [ | Adenocarcinoma of the uterus | − | NI |
| Enomoto et al. [ | Early-stage gastric carcinoma | + | NI |
| Denschlag et al. [ | Fallopian tube carcinoma | − | NI |
| Giannakopoulos et al. [ | Ovarian adenocarcinoma | − | NI |
| Yogarajah et al. [ | Ovarian adenocarcinoma | NI | NI |
| Bolibar et al. [ | Ovarian adenocarcinoma | − | NI |
| Preda et al. [ | Ovarian adenocarcinoma | NI | NI |
| Krishna et al. [ | Breast cancer | − | NI |
| Qureshi and Saavedra [ | Ovarian adenocarcinoma | − | NI |
| Clarke et al. [ | Transitional cell carcinoma of the bladder | − | NI |
| Nahar and Al-Rajhi [ | Ovarian adenocarcinoma | − | NI |
| Sandhya and Danda [ | Breast carcinoma | NI | NI |
| Mcgivern and Mcaleese [ | NSCLC | NI | NI |
| Salmon et al. [ | Ovarian adenocarcinoma | − | NI |
| Salmon et al. [ | Ovarian adenocarcinoma | − | NI |
| Salmon et al. [ | Uterine cancer | NI | NI |
| Shetty et al. [ | Neuroendocrine tumour of adrenal gland | − | NI |
Box 1Box 1: Features of cancer polyarthritis (Stummvoll et al. [3], Larson et al. [8], Caldwell and McCallum [57], and Pfitzenmeyer et al. [58]).